Trial Profile
A Phase I Dose-Escalation Study of Erlotinib in Combination with Cetuximab in Subjects with Advanced Cancer. Companion study to umbrella protocol 2007-0638.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Erlotinib (Primary)
- Indications Cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jul 2013 Planned end date changed from 1 Apr 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov.
- 06 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center